Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
সব দামের পরিবর্তন →ইঙ্গিত ও ব্যবহার
MIF is indicated: As a medical alternative to surgical termination of intra-uterine pregnancy Softening and dilatation of the cervix uteri prior to surgical pregnancy termination Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reasons Labour induction for the expulsion of a dead fetus (fetal death in utero).
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
As a medical alternative to surgical termination of intra-uterine pregnancy in early pregnancy: a single oral dose of 600 mg Mifepristone is taken, followed 36 to 48 hours later by a prostaglandin analogue, either Misoprostol 400 mcg taken orally (for pregnancies up to 49 days) or Gemeprost 1 mg given vaginally (for pregnancies up to 63 days). For softening and dilatation of the cervix uteri before surgical termination of pregnancy: 200 mg Mifepristone is given, followed 36 to 48 hours later (but not later than that) by the surgical termination of pregnancy. As preparation for the action of prostaglandin analogues when terminating a pregnancy for medical reasons, in order to reduce the required doses of prostaglandin: a single oral dose of 600 mg Mifepristone is taken 36 to 48 hours before the scheduled prostaglandin administration, which is then repeated as often as needed. For induction of labour to expel a dead fetus (fetal death in utero): 600 mg of Mifepristone is taken as a single oral dose, once daily, for 2 consecutive days. Mifepristone alone brings about expulsion in around 60% of cases. If labour has not begun within 72 hours of the first Mifepristone dose, it should be induced using the usual methods. Use in children: safety and effectiveness in pediatric patients have not been established.
পার্শ্বপ্রতিক্রিয়া
Uterine contractions or cramping are very common in the hours after taking the prostaglandin, affecting roughly 10 to 45% of women. Bleeding tends to be heavier with more advanced gestational age, with heavy bleeding occurring in about 5% of cases; of these, roughly 0 to 1.4% may need haemostatic curettage. Uterine rupture, low blood pressure, skin rashes, hives, hot flashes and dizziness have been reported uncommonly.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Mifepristone (MIF) comes only in single-dose packaging and must be given under the supervision of a qualified physician. Its safety and effectiveness have not been studied in women with chronic conditions such as cardiovascular, hypertensive, hepatic, respiratory or renal disease; insulin-dependent diabetes mellitus; severe anemia; or heavy smoking. Women over 35 who smoke 10 or more cigarettes a day should be treated with caution, since such patients were generally excluded from MIF's clinical trials. No clinical evidence confirms it, but MIF may work less effectively if misoprostol is given more than two days after it.
নিষেধাজ্ঞা
Mifepristone should not be used if there is any uncertainty about whether the pregnancy exists or how far along it is, or if an ectopic (outside-the-womb) pregnancy is suspected. An ultrasound scan and/or a Beta-hCG measurement should be carried out before the medicine is given. For first-trimester abortion, Mifepristone is not recommended once the pregnancy has passed 49 days since the last menstrual period if it is being combined with Misoprostol, or 63 days if combined with Gemeprost. Mifepristone should never be given to patients with chronic adrenal failure, a known allergy to Mifepristone or any of its ingredients, severe asthma that is not controlled by corticosteroid treatment, porphyria, kidney or liver failure, malnutrition, or during breastfeeding. Mifepristone is a fat-soluble compound and may in theory pass into breast milk, though no data on this are currently available.